Intervention
- 90% of patients are included in the randomization of patients with an ECOG PS of 0–1 and at least a 3+ year duration of disease progression under a previous therapy
- Formal study end at the time of ceasing of EVE+EXE
- 3-monthly follow-up after the formal study end

Methods
- Randomization was 1:1 into EVE+EXE (n = 497) vs. PBO+EXE (n = 497)
- Interim analysis after 75% of patients reached the formal study end
- Formal study end reached by 2 patients
- Missing data in 18.8% of patients

Results
- Median time from first diagnosis of recurrence/metastases
- Postsocial Security Administration (n = 495)
- 2.7 years (95% CI, 2.3–3.1)

Discussion
- This study included postmenopausal women with first diagnosis in advanced setting
- 28% treatment for advanced disease
- 7% progression under a previous therapy

References
- BOLERO 2, which included pleural and peritoneal involvement
- North, Central and South Americas;
- Caribbean; China
- +18324604729
- +447860024038